What is new in chronic myeloid leukaemia?
Chronic myeloid leukaemia is a relatively rare condition, though it has stimulated widespread interest as a consequence of both the stem cell basis and the success of rationally designed therapies. This review will outline some of the issues involving the aetiology of the disease and how this relates to current and future therapies.
Heaney
N B
NB
ATMU, Cancer Division, Section of Experimental Haematology & Haemopoietic Stem Cells, University of Glasgow, UK.
Holyoake
T L
TL
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D064127:Aurora Kinases; D001549:Benzamides; D016026:Bone Marrow Transplantation; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm; D006529:Hepatomegaly / Q000209:etiology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000628:therapy*; D007964:Leukocytosis / Q000209:etiology; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D013163:Splenomegaly / Q000209:etiology; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D064127:Aurora Kinases; D017346:Protein Serine-Threonine Kinases; C498826:nilotinib; D000069439:Dasatinib